Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Appointed director
Verrica Pharmaceuticals Inc. (VRCA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results"
05/09/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results"
03/06/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results"
11/07/2022 8-K Quarterly results
Docs: "Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results"
08/11/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/02/2022 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results"
05/07/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Verrica Pharmaceuticals Reports Third Quarter 2020 Financial Results"
08/05/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "FORM 8-K",
"Verrica Pharmaceuticals Reports First Quarter 2020 Financial Results"
03/13/2020 8-K Quarterly results
Docs: "Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results",
"Verrica Pharmaceuticals Secures $55 Million in Loan Facilities Led by Silicon Valley Bank March 11, 2020 WEST CHESTER, Pa., March 11, 2020 — Verrica Pharmaceuticals Inc. , a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that it has entered into a mezzanine loan and security agreement with Silicon Valley Bank and WestRiver Innovation Lending Fund VIII, L.P., pursuant to which the lenders have agreed to lend the Company up to $50.0 million in a series of term loans. In addition, the Company entered into a loan and security agreement with SVB, pursuant to which SVB has agreed to provide the Company a revolving line of credit of up to $5.0 million. “The capital available under these facilities will support the p..."
11/06/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Verrica Pharmaceuticals Reports Third Quarter 2019 Financial Results"
08/07/2019 8-K Quarterly results
Docs: "Verrica Pharmaceuticals Reports Second Quarter 2019 Financial Results"
05/07/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Verrica Pharmaceuticals Reports First Quarter 2019 Financial Results"
03/07/2019 8-K Quarterly results
Docs: "Verrica Reports Fourth Quarter and Full Year 2018 Financial Results"
11/07/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 7, 2018 Verrica Pharmaceuticals Inc. Delaware 001-38529 46-3137900 10 North High Street, Suite 200 West Chester, PA 19380 Registrant's telephone number, including area code: 453-3300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-c...",
"Verrica Pharmaceuticals Reports Third Quarter 2018 Financial Results"
08/07/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Verrica Reports Second Quarter 2018 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy